Garuda Therapeutics, founded in Cambridge, Massachusetts, is dedicated to developing off-the-shelf hematopoietic stem cell (HSC) therapies aimed at treating severe and life-threatening diseases. The company's core mission is to provide accessible and ready-to-use stem cell treatments, revolutionizing the approach to managing critical health conditions. Garuda's vision is to make advanced stem cell therapies widely available, thereby improving patient outcomes across various demographics and medical needs.
Notable figures affiliated with Garuda Therapeutics include Dhvanit Shah, Ph.D., who serves as Co-founder, President, and Chief Executive Officer. The company has garnered attention for its innovative approach and has been recognized by industry awards such as the BioTech Breakthrough Awards. Garuda Therapeutics' impact lies in its potential to transform the landscape of stem cell therapy, offering scalable and immediate solutions for patients in need.
